Expression of kisspeptin and its receptor in different functional classes of ovarian follicle in the buffalo (Bubalus bubalis)
in Nature (1980)
Its mechanism involves activating the AMPK/SIRT1 pathways and suppressing lipogenic regulators like PPAR and SREBP-1c, highlighting its potential as a therapeutic candidate for NAFLD (96)
FOXO4-DRI + NAD+ Combines senescent cell removal with mitochondrial and cellular energy support
Currently, an ongoing phase III, multicenter, randomized, sham-controlled, double-blind trial is evaluating AT-04s efficacy and safety for endometriosis-related pain (dysmenorrhea, dyspareunia, chronic pelvic pain), with the primary outcome being the change in Numeric Rating Scale score at 16 weeks ( 4.5 Disease heterogeneity and subtype-specific therapeutic strategies Endometriosis exhibits significant clinical and biological heterogeneity, encompassing diverse anatomical subtypessuperficial peritoneal endometriosis (SPE), ovarian endometriomas (OMA), and deep infiltrating endometriosis (DIE)each with distinct pathophysiological features, symptom profiles, and fertility implications ( Table 1 )
